25T7-NBOMe
A synthetic psychedelic compound
| 25T7-NBOMe | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
25T7-NBOMe is a synthetic psychedelic compound belonging to the NBOMe series. It is a derivative of the phenethylamine 2C-T-7, and is known for its potent hallucinogenic effects.
Chemical structure and properties
25T7-NBOMe is chemically classified as a phenethylamine and a substituted amphetamine. Its structure includes a 2,5-dimethoxyphenethylamine core with an isopropylthio group at the 4-position and a 2-methoxybenzyl group attached to the nitrogen atom. This modification is responsible for its high affinity for the 5-HT2A receptor, which is thought to mediate its psychedelic effects.
Pharmacology
25T7-NBOMe acts primarily as a potent agonist of the 5-HT2A receptor, similar to other compounds in the NBOMe series. This receptor is a subtype of the serotonin receptor and is heavily involved in the modulation of mood, perception, and cognition. The activation of this receptor by 25T7-NBOMe is believed to be responsible for its psychedelic effects, which can include altered visual and auditory perceptions, changes in thought patterns, and an altered sense of time.
Effects
The effects of 25T7-NBOMe are similar to those of other psychedelics, such as LSD and psilocybin. Users report intense visual hallucinations, euphoria, and a sense of connection with the universe. However, the compound is also associated with adverse effects, including anxiety, paranoia, and, in some cases, dangerous physiological reactions such as tachycardia and hypertension.
Legal status
The legal status of 25T7-NBOMe varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. It is important for researchers and users to be aware of the legal implications of possessing or distributing this compound.
Safety and toxicity
The safety profile of 25T7-NBOMe is not well-established, and there have been reports of severe adverse reactions and fatalities associated with its use. The compound's potency and the variability in individual responses make it particularly risky. Users are advised to exercise caution and to be aware of the potential for overdose.
Related pages
Gallery
-
Chemical structure of 25T7-NBOMe
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian